Results 121 to 130 of about 826 (178)

Assessment of pharmacokinetic interaction of L-dopa and benserazide : animal model, mechanistic mathematical models, and allometric scaling across species [PDF]

, 2004
Grange, Susanna Sarah
core   +1 more source

Physiologically Based Biopharmaceutics Modeling (PBBM): Best Practices for Drug Product Quality, Regulatory and Industry Perspectives: 2023 Workshop Summary Report. [PDF]

Mol Pharm
Mackie C, Arora S, Seo P, Moody R, Rege B, Pepin X, Heimbach T, Tannergren C, Mitra A, Suarez-Sharp S, Borges LN, Kijima S, Kotzagiorgis E, Malamatari M, Veerasingham S, Polli JE, Rullo G.   +16 more
europepmc   +1 more source

Application of New Approach Methodologies to Improve Oral Biopharmaceutic Assessments. [PDF]

Pharmaceutics
García MA, Cabrera-Pérez MÁ, González PM, Aceituno A, Hachim D.   +4 more
europepmc   +1 more source

Bioaccessibility of potentially harmful elements (PHEs) from environmental matrices and implications for human health

Internationally publicized impacts upon human health associated with exposure to potentially harmful elements (PHE) have been reported globally.
Boisa, Ndokiari
core  

Open Systems Pharmacology Community Conference (OSP-CC) Proceedings 2025. [PDF]

CPT Pharmacometrics Syst Pharmacol
Cordes H, Annaert P, Balazki P, Benamara S, Bonan RH, Butler A, Chenel M, Cui Y, Dallmann A, de Witte WEA, Demeester C, Feick D, Gattacceca F, Geci R, Gerebtzoff G, Gruber A, Guimarães M, Hamadeh A, Hanke N, Ibarra M, Ince I, Kanacher T, Kuepfer L, Mil F, Montaseri G, Nauwelaerts N, Proenca S, Schaller S, Schlender JF, Schneider ARP, Sjögren E, Solodenko J, Staab A, Vrenken P, Troisi C, Teutonico D.   +35 more
europepmc   +1 more source

Physiologically Based Biopharmaceutics Modelling-Best Scientific Practices to Define Drug Product Performance, Latest Regulatory and Industry Perspectives: Workshop Summary Report. [PDF]

Pharmaceutics
McAllister M, Mistry N, Pepin X, Cole S, Tannergren C, Stamatopoulos K, Engman H, Moir A, Litou C, Gavins F, Arora S, Malamatari M, Guimarães M, Ravi A, Fotaki N, Dodd L, Holte Ø, Butler J, Dickinson PA, Popkin M, Butler A, NiOgain O, Holmstock N, Mackie C.   +23 more
europepmc   +1 more source

Advancing Pharmacoequity in Low- and Middle-Income Countries via Model Informed Drug Development. [PDF]

Clin Transl Sci
Enzama H, Ojara FW, Haworth IS, Cvijic S, Waitt C, Grasela TH.   +5 more
europepmc   +1 more source

Integration of Machine Learning With PBPK and QSAR Modeling Approaches to Facilitate Drug Discovery and Development. [PDF]

CPT Pharmacometrics Syst Pharmacol
Chen X, Lin Z.
europepmc   +1 more source

Evaluation of USP 3 Apparatus to Develop Biopredictive Fasted and Fed Dissolution Methods for Extended-Release Desvenlafaxine Succinate Tablets. [PDF]

ACS Omega
Carapeto GV, Nunes BC, Duque MD, Issa MG, Ferraz HG.   +4 more
europepmc   +1 more source

Exploring Tafamidis Effects Through PBPK-QSP Modelling. [PDF]

Pharmaceutics
Ulaszek S, Lisowski B, Wiśniowska B, Polak S.   +3 more
europepmc   +1 more source